afternoon, months joining transpired Thanks, that and everyone, we safe two since in call over ago, Good pandemic. stayed Bruce. your thank Much families COVID-XX you hope of our and face well us. last the barely you and sincerely in have has and investor world the for the
is As indeed hear safe well. Codexis you today, and will
than a moderately note To the while the through pandemic. place in term, multi-year delivering the well balance the entered effects our pre affected resources are more remarkably that trajectory And start, were short as firmly coronavirus substantial But growth had sheet. organization. we even ever. of We our pandemic stronger in we strengths about we the debt-free operate on and
disciplined an that leadership initiated, times. unprecedented have primary before Even formalized task launched for seasoned, than exploiting us Dr. Area Bay Sato, Head to Ensuring team protein and crucial which team distancing, of and practicing were San We driving capacity the and Francisco discovery CodeEvolver super their technology. us. ever before safety leadership shelter-in-place family team platform a more growing orders talented ever-improving of has been the measures lead Quality, we social through I and under Analytical, of long-standing our has Regulatory and Bob these our COVID-XX force and have been the were
society what's appreciate cohesive more our our our group infection concern down of affected being culture benefits With and our company-wide a their cases and COVID-XX No are even policy, The clear employees, of March doing point. this of best we research and motivated shelter-in-place issued an on operations. who well-being genuine for of smoothly confirmed community. of and the orders proactive swiftly development XX, ensuing management's any at for strengthening by work-from-home shutting effectively
Researchers remarkable. of to ensure our force have time to chain protein been there, teams double define targets doing collective for for our to and From continue Supply to in attitudes teams us through needs pandemic pursue. gathering pictures products strategic customer the -- virtually organization to quarantine driven new flow the teams the inefficiencies, of et electronic progress bulletin corporation. despite company bullet for the pharmaceutical board with collaborating teams, board, new And against of make essential similarly manufacturing. affected cetera. delivering the Codexis sharing encouragement, goals core the
makes us Here, the list equally proud.
their practice. landmark and competent with get better-than-expected lab operation forged We the equally pandemic. biotherapeutic external in operations remote We quarter first by the joint Takeda with despite inked shortened their have middle largely pandemic. to that supply successfully for collaborated the shelter-in-place. in ensured approaches, partnering partners, supported operational lab by manufacturing the revenues being The chain core the We continuous revenue and enzyme by our limitations manufacturing of CodeEvolver effectively ready to our have activities product and operations that remains deal despite new initiated unaffected R&D of delivered stream a Novartis established team has outstanding
support shelter-in-place R&D And are we learning us customers in to strict we governments started our capacity local R&D phased effectively and In safe we R&D limited socially And of that place. more ordinances businesses. that and learning distancing up a back this a protein so restart, activities process again discovery have when and essential social currently way, to conducting to in how workflow rapid in of ramp will our operations distanced modify limited in the recently, ensure and relax safely at are tandem. enable the
but been have R&D restrictions, projects. R&D since that time-based only shelter-in-place revenues portion, affected the a are customer-partnered, those effectively, mid-March most revenues
given XXXX time that impossible our this point, of predict company at limitations. components less by accurately financial course of As operational magnitude withdrawing restrictions to are these the we expected represent R&D prudent are impacted to taking a revenues, our contrast, are of In over total meaningful other our R&D revenues be the portion guidance. and of our
our had preserve third-party cash pandemic. engineering or and and to delaying XXXX, but we addition, commercialization those from in able revenues the the help vast additions to mitigate capacities headcount spending. much to flow through reducing In been have purchases We impact the been have through of add majority of to R&D reduced postponed protein capital intelligently cash plans
However, rest several experiences. unprecedented our and strategic brings development, team crucial we and Stephan announced regarded the synthetic doctors research and complements It that engineering is Stefan the are pleased of Lutz slide protein long Karl us have industry. stage and technology team well-known Schoene over as the to scale they in knowledge given highly lead are our his the arrivals biology this broad-based Codexis commercial and within and efforts hiring of Karl our recently team. Stephane is to in to term. continued executive to strengthen up,
to of networked annual as and as upcoming Similarly, Amgen through Dr. two build officer chief vote Genentech, technology beyond Moore board pioneering us for and Stephan in proxy spanning join great to talented Therapeutics, our have at clinical-stage and we is and Alison a meeting. excited Karl is career company attracted CAR-T now members highly development prospective It are have a we a pharmaceutical with Allogene pandemic. veteran the therapeutics.
FDA CEO stage and Allison to Dilly drug notably, of most Stephen has recently its Complementing first development served clinical rest received recently which the having Codexis, our Aimmune approval. drug Therapeutics, of as Dr. brings experience leadership board, substantial
biotechnology confidence and the me Before and summarize person them. handing company for, strength the our our to caring financials, our success of Ross organization ongoing XXX-plus our let over is in to our retaining, in At core Codexis. detail talented igniting great of
are are adjust They exceptional to ways responding brilliantly the as in delivering and pandemic. we
great and of strengthen selectively us we companies We and list as partners. to even are serve talent we continue smartly unique grow attracting collaborative the to new, make stronger, and proudly
to confident be the for times financial review We are equipped of over an With Ross? other to me Codexis to the are a our better turn performance. these weather poised that, call stronger, even and uncertain let side. Ross on
